PHENOMICS HEALTH
DEAD

Serial Number

97023072

Owner

Phenomics Health Inc.

Attorney

Roger H. Bora

Filing Date

Sep 12, 2021

Add to watchlist:

No watchlists yet
View on USPTO

PHENOMICS HEALTH Trademark

Serial Number: 97023072

PHENOMICS HEALTH is a trademark filed by Phenomics Health Inc. on September 12, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Phenomics Health Inc. (11 trademarks)

60 Yorkshire Drive
Hilton Head Island, SC 29928

Entity Type: 03

Trademark Details

Filing Date

September 12, 2021

Registration Date

Not Registered

Goods & Services

Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions, namely, testing, analysis and evaluation of blood and other biological samples for clinical treatment decision support purposes; Medical testing, analysis, and evaluation services in the nature of testing, analysis and evaluation of blood samples for diagnostic and treatment purposes; Medical testing, analysis, and evaluation services relating to the diagnosis and treatment of disease and other medical conditions in the nature of testing, analysis and evaluation of blood samples for the purpose of combining increased predictability of patient-specific drug efficacy, appropriate dose, drug-drug interactions, and likely adverse drug reactions with precise measurement of patient response to improve patient treatment outcomes, avoid adverse drug reactions, and reduce patient treatment costs

Scientific and technological services featuring testing, analysis and evaluation of human blood and other biological samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services featuring testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; Software as a service (SaaS) services featuring software for use in medical research data collection and management and database management, allowing physicians to share and receive clinical data, monitor patient data, monitor patient clinical data, monitor medications in a patient's circulation to support treatment decisions, develop clinical treatment decision support, develop other medical diagnostic products and prescription drugs for the purpose of improving patient outcomes in the field of healthcare, analyze and record testing, analysis and evaluation of human blood and other biological samples for the purposes of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving the initial drug prescribing practices, and identifying drug-drug interactions; Platform as a Service (PaaS) featuring computer software that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; Providing an interactive website featuring technology that allows users to monitor patient data, patient clinical data, and medications in a patient's circulation to support treatment decisions; scientific and technological services, namely, providing medical and scientific research featuring testing, analysis and evaluation of blood samples for the purpose of improving the identification and quantitative measurement of patient drug exposure, improving the monitoring and diagnosis of patient drug compliance, improving drug selection and dosage recommendations, improving initial drug prescribing practices, identifying drug-drug interactions, developing clinical treatment decision support, and developing other medical diagnostic products and prescription drugs; scientific and technological services in the nature of testing, analysis and evaluation of blood and other biological samples for research purposes in the field of clinical trials; scientific and technological services, namely, research, analysis, and clinical testing in the fields of precision medicine for the purpose of combining pharmacogenomic drug treatment recommendations, identification and quantitative measurement of patient drug exposure with digital patient monitoring and digital therapy

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 3, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 3, 2025 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 11, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 11, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 14, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 14, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 14, 2024 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 29, 2023 RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 18, 2023 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 1, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 1, 2023 GNSL
SUSPENSION LETTER WRITTEN
Feb 1, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 3, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 3, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 3, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 5, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 5, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 5, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 15, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 19, 2021 NWOS
NEW APPLICATION ENTERED
Sep 15, 2021 NWAP